Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

The hope and the reality of reduced intensity transplants in children with malignant diseases

Summary:

Reduced intensity preparative regimens are increasingly used for conditioning prior to allogeneic stem cell transplantation. As opposed to classical methods of pre-transplant conditioning, patients receive predominantly immunosuppressive therapies that facilitate early engraftment, while cells within the graft itself promote continuation of the engraftment process. Despite early hopes that this form of transplant would be devoid of grade III and IV acute toxicities, there is a substantial amount of short-term morbidity associated with the technique. Although long-term follow-up is not yet available, it is hoped that these regimens will spare young patients many of the late effects (cataracts, growth retardation, endocrine and reproductive problems) that are often associated with classical pre-transplant conditioning regimens. Reliable engraftment and leukemic control have been demonstrated in a large number of both adult and pediatric transplant recipients of these regimens, many of whom were deemed at high risk for standard conditioning because of serious co-morbidities, previous autologous transplantation or multiply relapsed disease. A brief review of the state of the art of this technology as it applies to pediatric transplantation is presented. Preliminary results of a survey of pediatric transplant centers indicate that a variety of protocols are used for a variety of indications. The use of standardized criteria for implementation of reduced intensity preparative regimens, the use of a limited number of regimens, and more extensive data collection will permit the elaboration of prospective comparative studies of this new and exciting modality.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Dufour C, Rondelli R, Locatelli F et al. Stem cell transplantation for HLA-matched related donor from Fanconi's anemia: a retrospective review of the multicenter Italian experience on behalf of AIEOP-GITMO. Br J Haematol 2001; 112: 796–805.

    Article  CAS  Google Scholar 

  2. Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow Transplantation. On behalf of the working party on severe aplastic anemia of the European group for blood and marrow transplantation. Acta Haematol 2000; 103: 19–25.

    Article  CAS  Google Scholar 

  3. Buckley RH . Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res 2000; 22: 237–251.

    Article  CAS  Google Scholar 

  4. Rubocki RJ, Parsa JR, Hershfield MS et al. Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency. Blood 2001; 97: 809–811.

    Article  CAS  Google Scholar 

  5. Kolb HJ, Simoes B, Schmid C . Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 2004; 16: 167–173.

    Article  Google Scholar 

  6. Askenasy N, Farkas DL . Antigen barriers or available space do not restrict in situ adhesion of hemopoietic cells to bone marrow stroma. Stem Cells 2002; 20: 80–85.

    Article  Google Scholar 

  7. Huss R, Deeg HJ, Gooley T et al. Effect of mixed chimerism on graft vs host disease, disease recurrence and survival after HLA identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767–776.

    CAS  Google Scholar 

  8. Andreani M, Nesci S, Lucarelli G et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–405.

    Article  CAS  Google Scholar 

  9. Fink PJ, Shimenkevits RP, Bevan MJ . Veto cells. Ann Rev Immune 1988; 6: 115–137.

    Article  CAS  Google Scholar 

  10. Reich Zelliger S, Zhao Y, Krauthgamer R et al. Anti-third party CD8+ CTLs as potent veto cells. Coexpression of CD8 and Fas L as a perquisite. Immunity 2000; 13: 507–515.

    Article  Google Scholar 

  11. Bachar-Lustig E, Reich Zeliger S, Gur H et al. Bone marrow transplantation across major genetic barriers: the role of megadose stem cells and nonalloreactive donor anti-third party CTLS. Transplant Proc 2001; 33: 2099–2100.

    Article  CAS  Google Scholar 

  12. Reisner Y, Gur H, Reich-Zeliger S et al. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann NY Acad Sci 2003; 996: 72–79.

    Article  CAS  Google Scholar 

  13. Socie G, Salooja N, Cohen A et al. Nonmalignant late effect after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.

    Article  CAS  Google Scholar 

  14. Gomez-Almagur D, Ruiz-Arguilles GJ, Tarin-Argaza D et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003; 9: 157–161.

    Article  Google Scholar 

  15. Ruiz-Arguelles GJ . Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int J Hematol 2002; 76: 376–379.

    Article  Google Scholar 

  16. Del Toro G, Satwani P, Harrison L et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613–622.

    Article  CAS  Google Scholar 

  17. Hogan WJ, Maris M, Storer B et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78–84.

    Article  CAS  Google Scholar 

  18. Das M, Saikia TK, Advani SH et al. Use of reduced intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125–129.

    Article  CAS  Google Scholar 

  19. Junghanss C, Storb R, Maris MB et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003; 123: 662–670.

    Article  Google Scholar 

  20. Caravalo C, Geller N, Kurlander R et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004; 103: 1560–1563.

    Article  Google Scholar 

  21. Dror Y, Freedman MH, Leaker M et al. Low intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in dyskeratosis congenital. Bone Marrow Transplant 2003; 31: 847–850.

    Article  CAS  Google Scholar 

  22. Pavletic SZ, Bociek RG, Foran JM et al. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation 2003; 76: 877–881.

    Article  CAS  Google Scholar 

  23. Maris MB, Storb R . The transplantation of hematopoietic stem cells after nonmyeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003; 28: 13–24.

    Article  Google Scholar 

  24. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporin and mycophenolate mofetil can induce durable complete chimerism and sustained remissions in patients with hematological disease. Blood 2003; 101: 1620–1629.

    Article  CAS  Google Scholar 

  25. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756–763.

    CAS  Google Scholar 

  26. Giralt S, Estey E, Labitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft vs leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  Google Scholar 

  27. Khouri I, Champlin RE . Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004; 31: 22–26.

    Article  Google Scholar 

  28. Iannone R, Casella JF, Fuchs EJ et al. Results of minimally toxic non-myeloablative transplantation in patients with sickle cell anemia and beta thalassemia. Biol Blood Marrow Transplant 2003; 9: 519–528.

    Article  Google Scholar 

  29. Langer T, Beck JD, Gravou-Apostalatou C et al. Successful treatment of primary refractory acute myeloid leukemia with megadose stem cell transplantation, bone marrow boost and reduced intensity conditioning avoiding chronic graft vs host disease and severe late toxicity. Pediatr Transplant 2003; 7: 494–496.

    Article  Google Scholar 

  30. Berger M, Vassalo E, Nesi F et al. Successful unrelated cord blood transplantation following reduced intensity conditioning for refractory acute myeloid leukemia. J Pediatr Hematol Oncol 2004; 26: 98–100.

    Article  Google Scholar 

  31. Nobili B, Rossi G, De Stefano P et al. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-base reduced-intensity conditioning regimen. Br J Hematol 2002; 119: 573–574.

    Article  Google Scholar 

  32. Ueno NT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829–3836.

    Article  CAS  Google Scholar 

  33. Claviez A, Klingebiel T, Beyer J et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 2004; 83: 237–241.

    Article  Google Scholar 

  34. Matthes-Martin S, Lion T, Haas OA et al. Lineage-specific chimerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimerism for late graft rejection. Leukemia 2003; 17: 1934–1942.

    Article  CAS  Google Scholar 

  35. Bethge WA, Hegenbart U, Stuart MJ et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790–795.

    Article  CAS  Google Scholar 

  36. Rocha V, Cornish J, Sievers EL et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962–2971.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to I Yaniv.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stein, J., Dini, G., Yaniv, I. et al. The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 35 (Suppl 1), S39–S43 (2005). https://doi.org/10.1038/sj.bmt.1704845

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704845

Keywords

This article is cited by

Search

Quick links